Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.95
Atara Biotherapeutics, Inc. issued up to 400,000 shares of the Company's Common Stock of warrant to HCR Molag Fund, L.P. for exercise price is equal to $0.0001 per share.
- Security
- warrant
- Shares
- up to 400,000 shares of the Company's Common Stock
- Purchaser
- HCR Molag Fund, L.P.
- Consideration
- exercise price is equal to $0.0001 per share
Exact text from the filing
the Company issued a warrant to purchase up to 400,000 shares of the Company's Common Stock (the “Warrant”). The exercise price of the Warrant is equal to $0.0001 per share, subject to adjustment as provided therein, and the Warrants will be exercisable immediately and has no expiration date.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Atara Biotherapeutics, Inc. amended Amendment with HCR Molag Fund, L.P. valued at $9.0 million (effective 2026-02-20).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- HCR Molag Fund, L.P.
- Value
- $9.0 million
- Effective
- 2026-02-20
Exact text from the filing
On February 20, 2026, Atara Biotherapeutics, Inc., (the “Company”) entered into an Amendment (the “Amendment”) to the Purchase and Sale Agreement dated as of December 20, 2022 (the “Agreement”) with HCR Molag Fund, L.P. (“HCR”). Under the terms of the Amendment, HCR agreed to amend the due date of the one-time of $9.0 million cash payment
View on SEC.gov